Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
Despite recent advances in multimodality therapy for glioblastoma (GB) incorporating surgery, radiotherapy, chemotherapy and targeted therapy, the overall prognosis remains poor. One of the interesting targets for GB therapy is the histone deacetylase family (HDAC). Due to their pleiotropic effects...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2023-02-01
|
| Schriftenreihe: | Pharmaceuticals |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/1424-8247/16/2/227 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|